$INKT
MiNK Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021565 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.077M $4.651M $2.481M
YoY Change -49.89% 87.47%
% of Gross Profit
Research & Development $5.812M $6.150M $3.334M
YoY Change 168.18% 84.45% 33.16%
% of Gross Profit
Depreciation & Amortization $37.93K $28.43K $20.29K
YoY Change 59.17% 40.12%
% of Gross Profit
Operating Expenses $7.889M $6.150M $3.334M
YoY Change 24.98% 84.45% 33.16%
Operating Profit -$7.987M -$13.38M
YoY Change -40.29% 125.8%
Interest Expense $0.00 $92.96K $881.3K
YoY Change -100.0% -89.45% 37.92%
% of Operating Profit
Other Income/Expense, Net $120.0K $1.563M -$364.8K
YoY Change -79.96% -528.34% -170.18%
Pretax Income -$7.769M -$6.332M -$14.27M
YoY Change 34.78% -55.62%
Income Tax
% Of Pretax Income
Net Earnings -$7.769M -$6.332M -$14.27M
YoY Change 34.78% -55.62% 136.09%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.59
Diluted Earnings Per Share -$0.23 -$0.19 -$589.4K
COMMON SHARES
Basic Shares Outstanding 33.79M 33.78M 24.21M
Diluted Shares Outstanding 33.76M 24.21M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.64M $24.16M $819.5K
YoY Change -49.51% 2848.15%
Cash & Equivalents $19.60M $24.20M $819.5K
Short-Term Investments
Other Short-Term Assets $470.3K $37.52K $2.609M
YoY Change -36.81% -98.56%
Inventory
Prepaid Expenses $298.7K $262.9K
Receivables
Other Receivables
Total Short-Term Assets $20.40M $24.46M $3.442M
YoY Change -48.52% 610.7%
LONG-TERM ASSETS
Property, Plant & Equipment $1.067M $803.1K $635.9K
YoY Change 75.9% 26.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.067M $803.1K $635.9K
YoY Change 75.89% 26.3%
TOTAL ASSETS
Total Short-Term Assets $20.40M $24.46M $3.442M
Total Long-Term Assets $1.067M $803.1K $635.9K
Total Assets $21.47M $25.26M $4.077M
YoY Change -46.64% 519.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.823M $5.172M $1.648M
YoY Change 94.38% 213.78%
Accrued Expenses $4.239M $2.832M $3.085M
YoY Change 140.31% -8.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $65.42M
YoY Change
Total Short-Term Liabilities $12.68M $18.45M $80.56M
YoY Change -22.97% -77.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $108.5K $58.28K $27.54K
YoY Change 111.6%
Total Long-Term Liabilities $108.5K $58.28K $27.54K
YoY Change 111.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.68M $18.45M $80.56M
Total Long-Term Liabilities $108.5K $58.28K $27.54K
Total Liabilities $12.79M $18.51M $80.59M
YoY Change -22.31% -77.04%
SHAREHOLDERS EQUITY
Retained Earnings -$110.9M -$103.2M -$77.20M
YoY Change 33.7% 33.68%
Common Stock $110.8M $110.0M $1.462M
YoY Change 3.24% 7425.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$401.3K $6.756M -$76.51M
YoY Change
Total Liabilities & Shareholders Equity $21.47M $25.26M $4.077M
YoY Change -46.64% 519.56%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$7.769M -$6.332M -$14.27M
YoY Change 34.78% -55.62% 136.09%
Depreciation, Depletion And Amortization $37.93K $28.43K $20.29K
YoY Change 59.17% 40.12%
Cash From Operating Activities -$4.431M -$5.615M -$3.496M
YoY Change 160.27% 60.61%
INVESTING ACTIVITIES
Capital Expenditures $127.8K -$59.80K -$111.8K
YoY Change 45557.14% -46.52%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$127.8K -$59.80K -$111.8K
YoY Change -45757.14% -46.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 110.0 490.0 2.783M
YoY Change -100.0% -99.98%
NET CHANGE
Cash From Operating Activities -4.431M -5.615M -3.496M
Cash From Investing Activities -127.8K -59.80K -111.8K
Cash From Financing Activities 110.0 490.0 2.783M
Net Change In Cash -4.558M -5.674M -825.0K
YoY Change -111.97% 587.8%
FREE CASH FLOW
Cash From Operating Activities -$4.431M -$5.615M -$3.496M
Capital Expenditures $127.8K -$59.80K -$111.8K
Free Cash Flow -$4.558M -$5.555M -$3.384M
YoY Change 167.73% 64.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001840229
dei Entity Shell Company
EntityShellCompany
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33785929
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24158587
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10010
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
994-8250
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
INKT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity File Number
EntityFileNumber
001-40908
dei Entity Registrant Name
EntityRegistrantName
MiNK Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2142067
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38888828
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
262870
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1761
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
37520
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
744321
CY2022Q3 us-gaap Assets Current
AssetsCurrent
24458977
CY2021Q4 us-gaap Assets Current
AssetsCurrent
39634910
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
232756
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
168605
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
803128
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
606595
CY2022Q3 us-gaap Assets
Assets
25262105
CY2021Q4 us-gaap Assets
Assets
40241505
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5171551
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2995645
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2832389
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1763688
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2086899
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5760609
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
8356849
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
5945094
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18447688
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16465036
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
58280
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33785929
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33476523
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
338
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
335
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
110003410
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
107349265
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-78276
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-625269
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103169335
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82947862
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6756137
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23776469
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25262105
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10016449
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1837571
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40241505
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6149778
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3334126
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17303205
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
814881
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5756864
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2277759
CY2021Q3 inkt Change In Fair Value Of Convertible Affiliated Note
ChangeInFairValueOfConvertibleAffiliatedNote
9227427
inkt Change In Fair Value Of Convertible Affiliated Note
ChangeInFairValueOfConvertibleAffiliatedNote
9702863
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7987349
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13376434
us-gaap Operating Income Loss
OperatingIncomeLoss
-23060069
us-gaap Operating Income Loss
OperatingIncomeLoss
-21997071
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
92960
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-881323
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
118488
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2430067
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
355515
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
355515
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1562759
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-364844
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2720108
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-376819
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6331630
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14267086
us-gaap Net Income Loss
NetIncomeLoss
-20221473
us-gaap Net Income Loss
NetIncomeLoss
-24448442
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33757164
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33757164
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24205446
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24205446
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33627954
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33627954
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24186794
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24186794
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1375464
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
546111
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
546993
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
733702
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7707094
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13720975
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19674480
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23714740
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23776469
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7777101
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
522771
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
689
CY2022Q1 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
741773
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
43733
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
17308334
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6112742
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1399686
CY2022Q2 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
796924
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3886
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
301
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
75
CY2022Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
136330
CY2022Q2 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
157194
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13689838
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6331630
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1375464
CY2022Q3 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
745880
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
27019
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
494
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6756137
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-53874177
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3846194
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
353305
CY2021Q1 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
263081
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
19949
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-57084036
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6335162
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-165714
CY2021Q2 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
356097
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
51206
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-63177609
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14267086
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
546111
CY2021Q3 inkt Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Grant And Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsGrantAndRecognition
365760
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
21602
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
150
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-76511072
us-gaap Profit Loss
ProfitLoss
-20221473
us-gaap Profit Loss
ProfitLoss
-24448442
us-gaap Depreciation
Depreciation
83816
us-gaap Depreciation
Depreciation
54126
us-gaap Share Based Compensation
ShareBasedCompensation
2359215
us-gaap Share Based Compensation
ShareBasedCompensation
1077695
inkt Gain On Partial Forgiveness Of Liability
GainOnPartialForgivenessOfLiability
2790809
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
355515
inkt Interest Accrued On Convertible Affiliated Note
InterestAccruedOnConvertibleAffiliatedNote
2430067
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-477755
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2090462
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1504911
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1562717
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1224729
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2740954
inkt Change In Fair Value Of Convertible Affiliated Note
ChangeInFairValueOfConvertibleAffiliatedNote
9702863
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
261203
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-216799
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14436321
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11124834
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122208
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
249260
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-122208
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-249260
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1484
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
150
inkt Purchase Of Treasury Shares To Satisfy Tax Withholdings
PurchaseOfTreasurySharesToSatisfyTaxWithholdings
157194
inkt Proceeds From Issuance Of Convertible Affiliated Note
ProceedsFromIssuanceOfConvertibleAffiliatedNote
9459422
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-155710
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9459572
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-16002
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42816
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14730241
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1871706
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38888828
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2691156
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24158587
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
819450
us-gaap Interest Paid Net
InterestPaidNet
2546
inkt Purchases Of Plant And Equipment In Accounts Payable And Accrued Liabilities
PurchasesOfPlantAndEquipmentInAccountsPayableAndAccruedLiabilities
119629
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103200000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24200000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
802000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
531000
CY2022Q3 inkt Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
249000
CY2022Q3 inkt Accrued Research Services Current
AccruedResearchServicesCurrent
921000
CY2021Q4 inkt Accrued Research Services Current
AccruedResearchServicesCurrent
656000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2832000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1764000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4871822
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2060100
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.11
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
860000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
575000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
248744
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
194567
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
248237
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.44
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6240374
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4662974
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6240374
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4662974
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2807134
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M28D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3621767
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.15
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5400000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
723580
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
185794
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
125199
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
3.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
27830
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0.01
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
756345
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.00
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
1100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
772899
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
387362
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2359215
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1077695
CY2021Q4 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
5451958
inkt Impact Of Change In Fair Value Disclosure
ImpactOfChangeInFairValueDisclosure
9700000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9) Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may currently be, or may become, a party to legal proceedings. While the Company currently believes that the ultimate outcome of any of these proceedings will not have a material adverse effect on its financial position, results of operations, or liquidity, litigation is subject to inherent uncertainty and consumes both cash and management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>

Files In Submission

Name View Source Status
0000950170-22-021565-index-headers.html Edgar Link pending
0000950170-22-021565-index.html Edgar Link pending
0000950170-22-021565.txt Edgar Link pending
0000950170-22-021565-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inkt-20220930.htm Edgar Link pending
inkt-20220930.xsd Edgar Link pending
inkt-ex31_1.htm Edgar Link pending
inkt-ex31_2.htm Edgar Link pending
inkt-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
inkt-20220930_cal.xml Edgar Link unprocessable
inkt-20220930_pre.xml Edgar Link unprocessable
inkt-20220930_def.xml Edgar Link unprocessable
inkt-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
inkt-20220930_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending